Average Wholesale Price (AWP) and Pricing Benchmarks Explained for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), and other pharmaceutical pricing benchmarks are the frameworks defense attorneys and adjusters use to challenge pharmacy lien amounts. PI attorneys need to understand what these benchmarks measure, what they do not measure, and why they are not the appropriate standard for determining reasonable value in personal injury cases.

Average Wholesale Price (AWP) and Pricing Benchmarks Explained for PI Attorneys

Average Wholesale Price (AWP) is the most commonly cited pharmaceutical pricing benchmark in personal injury litigation, but it is widely misunderstood. AWP is a published reference price — sometimes called the "sticker price" of the drug industry — that serves as a starting point for reimbursement calculations across multiple payer types. It is not a market price, it is not what any entity actually pays for a drug, and it is not the standard for determining reasonable value of pharmacy services in personal injury cases.

• AWP (Average Wholesale Price) is a published benchmark used for reimbursement calculations, not an actual transaction price
• WAC (Wholesale Acquisition Cost) represents the manufacturer's list price to wholesalers before rebates or discounts
• Neither AWP nor WAC reflects what a pharmacy actually pays for a drug or what constitutes reasonable value in a PI context
• Defense attorneys who cite AWP or WAC as the "correct" price are applying an inapplicable framework to PI pharmacy services
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, understanding these pricing frameworks is essential for rebutting defense challenges to pharmacy lien amounts

The Major Pricing Benchmarks

Average Wholesale Price (AWP): Published by compendia like Medi-Span and Red Book, AWP is a reference price that historically represented a suggested wholesale list price. In practice, AWP is a benchmark from which discounts are calculated. Insurance reimbursement formulas are often expressed as "AWP minus X percent" plus a dispensing fee. AWP is not what wholesalers charge pharmacies, and it is not what pharmacies charge patients.

Wholesale Acquisition Cost (WAC): WAC is the manufacturer's published list price to wholesalers before any discounts, rebates, or chargebacks. Think of it as the manufacturer's starting number. Like AWP, WAC does not represent an actual transaction price because virtually all wholesale transactions involve negotiated discounts.

Maximum Allowable Cost (MAC): MAC lists are created by pharmacy benefit managers (PBMs) and insurance companies to set reimbursement ceilings for generic drugs. MAC prices vary between PBMs and are not standardized. They represent what a PBM is willing to pay, not what the drug costs or what constitutes its reasonable value.

340B Pricing: The 340B Drug Pricing Program provides deeply discounted drug prices to qualifying healthcare facilities. 340B pricing applies only to eligible entities and is not relevant to the general pharmacy market. Defense attorneys who cite 340B pricing as a benchmark for reasonable value are referencing a government program price that is legally unavailable to most pharmacies.

National Average Drug Acquisition Cost (NADAC): Published by the Centers for Medicare and Medicaid Services (CMS), NADAC represents a survey-based estimate of what pharmacies actually pay for drugs at the wholesale level. NADAC is the closest benchmark to actual pharmacy acquisition costs, but it represents a national average across pharmacy types and sizes.

Why These Benchmarks Are Irrelevant to PI Lien Pricing

Every pricing benchmark listed above was designed for a specific purpose within the insurance reimbursement ecosystem. None was designed to measure the reasonable value of pharmacy services in personal injury litigation. The distinction matters because:

Insurance reimbursement is a negotiated contract rate. When an insurance company reimburses a pharmacy at AWP minus 15% plus a $2.00 dispensing fee, that rate reflects a negotiated contract between the insurer and the pharmacy (or the PBM). It does not represent the reasonable market value of the service — it represents the price one buyer negotiated with one seller in a volume-based relationship.

PI pharmacy services carry risk that insurance transactions do not. A pharmacy dispensing under a lien assumes the risk that the case may not resolve favorably, that the settlement may be insufficient to cover the lien, or that payment may be significantly delayed. This risk profile has no parallel in the insurance reimbursement context, where payment is contractually guaranteed within defined timeframes.

The legal standard is reasonable value, not insurance rate. In personal injury cases across most jurisdictions, the measure of medical damages is the reasonable value of the services rendered — not what insurance would have paid. These are legally distinct standards, and defense attorneys who conflate them are applying the wrong framework.

How Defense Attorneys Misuse These Benchmarks

The most common defense tactic is to obtain AWP or WAC data for the medications on a pharmacy lien and argue that the lien amount exceeds these benchmarks, therefore the pricing is "unreasonable." This argument has several fundamental flaws:

First, AWP and WAC are not transaction prices. No entity in the pharmaceutical supply chain actually pays AWP or WAC for drugs. These are reference numbers from which actual prices are derived through negotiation.

Second, the comparison ignores the service component. A pharmacy lien includes not just the medication but the professional services associated with dispensing — pharmacist review, drug interaction screening, patient counseling, coordination with prescribers, documentation, and the administrative overhead of lien-based billing. For more on the documentation value pharmacists provide, see Pharmacy Counseling Notes as Symptom Documentation.

Third, the comparison ignores risk. Lien-based dispensing involves payment risk that cash or insurance transactions do not. The pricing framework must account for this risk, just as contingency fee structures account for the risk of attorney non-payment.

What Attorneys Should Know

When a defense expert or adjuster cites AWP, WAC, or any other pricing benchmark to challenge a pharmacy lien amount, the appropriate response is:

1. Identify the benchmark. Ask the defense to specify exactly which pricing reference they are using and acknowledge that it is a reimbursement benchmark, not a reasonable value standard.

2. Distinguish the context. Insurance reimbursement benchmarks apply to insurance-contracted transactions. PI pharmacy lien pricing applies to risk-adjusted, non-contracted professional services. These are different markets with different pricing dynamics.

3. Reference the legal standard. The question is not whether the lien amount exceeds AWP. The question is whether the lien amount represents the reasonable value of the pharmacy services in the relevant market — a factual question that a jury decides.

LienScripts generates a POGOS (Pharmacy-Organized General Occurrence Summary) report for every case, providing pharmacist-signed documentation for demand packages that includes clinical justification for each medication dispensed. This clinical documentation supports the reasonableness of the treatment, which in turn supports the reasonableness of the associated pharmacy services.

For additional strategies on responding to adjuster challenges, see Top Adjuster Attacks on Pharmacy Liens and How to Rebut Them.

Contact LienScripts to discuss pharmacy pricing benchmarks and how to respond to defense challenges to pharmacy lien amounts.